Innovate UK Offers Grant to Bicycle Therapeutics to develop next generation of novel antibiotics

Biotechnology company heralding a new class of therapeutics based on its bicyclic peptide product platform has been provided grant from Innovate UK to develop next generation of novel antibiotics. The Innovate UK funding will be used to develop Bicycles with unique properties and novel mechanisms of anti-bacterial action led by former CEO of Cantab anti-infectives. Bicycles are a fresh therapeutic modality that blends high affinity and splendid selectivity in a chemically synthesized format.

Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics said “Bicycles are structurally highly similar to many commonly prescribed natural product cyclic peptide antibiotics. Our enormously diverse compound library and highly efficient optimized screening approach will allow us to generate next generation antibiotics. We are grateful to Innovate UK for their vote of confidence and are looking forward to working with Mike Dawson to advance a much-needed novel approach in this extremely important area of research.”